Antibody-Dependent Cell Cytotoxicity
"Antibody-Dependent Cell Cytotoxicity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
| Descriptor ID |
D000920
|
| MeSH Number(s) |
G12.287.070
|
| Concept/Terms |
Antibody-Dependent Cell Cytotoxicity- Antibody-Dependent Cell Cytotoxicity
- Antibody Dependent Cell Cytotoxicity
- Cell Cytoxicity, Antibody-Dependent
- Antibody-Dependent Cell Cytoxicities
- Antibody-Dependent Cell Cytoxicity
- Cell Cytoxicities, Antibody-Dependent
- Cell Cytoxicity, Antibody Dependent
- Cytoxicities, Antibody-Dependent Cell
- Cytoxicity, Antibody-Dependent Cell
- ADCC
- Cytotoxicity, Antibody-Dependent Cell
- Antibody-Dependent Cell Cytotoxicities
- Cell Cytotoxicities, Antibody-Dependent
- Cell Cytotoxicity, Antibody-Dependent
- Cytotoxicities, Antibody-Dependent Cell
- Cytotoxicity, Antibody Dependent Cell
|
Below are MeSH descriptors whose meaning is more general than "Antibody-Dependent Cell Cytotoxicity".
Below are MeSH descriptors whose meaning is more specific than "Antibody-Dependent Cell Cytotoxicity".
This graph shows the total number of publications written about "Antibody-Dependent Cell Cytotoxicity" by people in this website by year, and whether "Antibody-Dependent Cell Cytotoxicity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibody-Dependent Cell Cytotoxicity" by people in Profiles.
-
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023 Mar 13; 14(1):1394.
-
Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res. 2018; 16(2):143-150.
-
Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy. J Infect Dis. 2017 07 01; 216(1):82-91.
-
NK Cell and Ig Interplay in Defense against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody-Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation. J Immunol. 2015 Aug 15; 195(4):1676-84.
-
Immunoglobulin GM and Fc?RIIIa genotypes influence cytotoxicity of neuroblastoma cells. J Neuroimmunol. 2014 May 15; 270(1-2):95-7.
-
Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes. Clin Exp Immunol. 2011 Dec; 166(3):361-5.
-
CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
-
The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma. PLoS One. 2009; 4(1):e4208.
-
Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res. 2007 Oct 01; 67(19):9535-41.
-
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul; 55(7):761-74.